News
The early-stage trial results signal promise for ISB 2001, a first-in-class trispecific antibody being developed for patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback